The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

Updates

• Notice of data discontinuation: Since the start of the pandemic, AP has reported case and death counts from data provided by Johns Hopkins University. Johns Hopkins University has announced that they will stop their daily data collection efforts after March 10. As Johns Hopkins stops providing data, the AP will also stop collecting daily numbers for COVID cases and deaths. The HHS and CDC now collect and visualize key metrics for the pandemic. AP advises using those resources when reporting on the pandemic going forward.

  • CDC Weekly case and death counts (national and state level)
  • CDC County level cases and deaths
  • HHS New hospital admissions
  • CDC NowCast COVID variant proportions (national and regional level)

• April 9, 2020

  • The population estimate data for New York County, NY has been updated to include all five New York City counties (Kings County, Queens County, Bronx County, Richmond County and New York County). This has been done to match the Johns Hopkins COVID-19 data, which aggregates counts for the five New York City counties to New York County.

• April 20, 2020

  • Johns Hopkins death totals in the US now include confirmed and probable deaths in accordance with CDC guidelines as of April 14. One significant result of this change was an increase of more than 3,700 deaths in the New York City count. This change will likely result in increases for death counts elsewhere as well. The AP does not alter the Johns Hopkins source data, so probable deaths are included in this dataset as well.

• April 29, 2020

  • The AP is now providing timeseries data for counts of COVID-19 cases and deaths. The raw counts are provided here unaltered, along with a population column with Census ACS-5 estimates and calculated daily case and death rates per 100,000 people. Please read the updated caveats section for more information.

• September 1st, 2020

  • Johns Hopkins is now providing counts for the five New York City counties individually.

• February 12, 2021

  • The Ohio Department of Health recently announced that as many as 4,000 COVID-19 deaths may have been underreported through the state’s reporting system, and that the "daily reported death counts will be high for a two to three-day period."
  • Because deaths data will be anomalous for consecutive days, we have chosen to freeze Ohio's rolling average for daily deaths at the last valid measure until Johns Hopkins is able to back-distribute the data. The raw daily death counts, as reported by Johns Hopkins and including the backlogged death data, will still be present in the new_deaths column.

• February 16, 2021

  - Johns Hopkins has reconciled Ohio's historical deaths data with the state.

  Overview

The AP is using data collected by the Johns Hopkins University Center for Systems Science and Engineering as our source for outbreak caseloads and death counts for the United States and globally.

The Hopkins data is available at the county level in the United States. The AP has paired this data with population figures and county rural/urban designations, and has calculated caseload and death rates per 100,000 people. Be aware that caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.

This data is from the Hopkins dashboard that is updated regularly throughout the day. Like all organizations dealing with data, Hopkins is constantly refining and cleaning up their feed, so there may be brief moments where data does not appear correctly. At this link, you’ll find the Hopkins daily data reports, and a clean version of their feed.

The AP is updating this dataset hourly at 45 minutes past the hour.

To learn more about AP's data journalism capabilities for publishers, corporations and financial institutions, go here or email kromano@ap.org.

Queries

Use AP's queries to filter the data or to join to other datasets we've made available to help cover the coronavirus pandemic

• Filter cases by state here

• Rank states by their status as current hotspots. Calculates the 7-day rolling average of new cases per capita in each state: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=481e82a4-1b2f-41c2-9ea1-d91aa4b3b1ac

• Find recent hotspots within your state by running a query to calculate the 7-day rolling average of new cases by capita in each county: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=b566f1db-3231-40fe-8099-311909b7b687&showTemplatePreview=true

• Join county-level case data to an earlier dataset released by AP on local hospital capacity here. To find out more about the hospital capacity dataset, see the full details.

• Pull the 100 counties with the highest per-capita confirmed cases here

• Rank all the counties by the highest per-capita rate of new cases in the past 7 days here. Be aware that because this ranks per-capita caseloads, very small counties may rise to the very top, so take into account raw caseload figures as well.

Interactive

The AP has designed an interactive map to track COVID-19 cases reported by Johns Hopkins.

@(https://datawrapper.dwcdn.net/nRyaf/15/)

Interactive Embed Code

<iframe title="USA counties (2018) choropleth map Mapping COVID-19 cases by county" aria-describedby="" id="datawrapper-chart-nRyaf" src="https://datawrapper.dwcdn.net/nRyaf/10/" scrolling="no" frameborder="0" style="width: 0; min-width: 100% !important;" height="400"></iframe><script type="text/javascript">(function() {'use strict';window.addEventListener('message', function(event) {if (typeof event.data['datawrapper-height'] !== 'undefined') {for (var chartId in event.data['datawrapper-height']) {var iframe = document.getElementById('datawrapper-chart-' + chartId) || document.querySelector("iframe[src*='" + chartId + "']");if (!iframe) {continue;}iframe.style.height = event.data['datawrapper-height'][chartId] + 'px';}}});})();</script>

Caveats

• This data represents the number of cases and deaths reported by each state and has been collected by Johns Hopkins from a number of sources cited on their website.
• In some cases, deaths or cases of people who've crossed state lines -- either to receive treatment or because they became sick and couldn't return home while traveling -- are reported in a state they aren't currently in, because of state reporting rules.
• In some states, there are a number of cases not assigned to a specific county -- for those cases, the county name is "unassigned to a single county"
• This data should be credited to Johns Hopkins University's COVID-19 tracking project. The AP is simply making it available here for ease of use for reporters and members.
• Caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.
• Population estimates at the county level are drawn from 2014-18 5-year estimates from the American Community Survey.
• The Urban/Rural classification scheme is from the Center for Disease Control and Preventions's National Center for Health Statistics. It puts each county into one of six categories -- from Large Central Metro to Non-Core -- according to population and other characteristics. More details about the classifications can be found here.

Johns Hopkins timeseries data - Johns Hopkins pulls data regularly to update their dashboard. Once a day, around 8pm EDT, Johns Hopkins adds the counts for all areas they cover to the timeseries file. These counts are snapshots of the latest cumulative counts provided by the source on that day. This can lead to inconsistencies if a source updates their historical data for accuracy, either increasing or decreasing the latest cumulative count. - Johns Hopkins periodically edits their historical timeseries data for accuracy. They provide a file documenting all errors in their timeseries files that they have identified and fixed here

Attribution

This data should be credited to Johns Hopkins University COVID-19 tracking project

Note: This COVID-19 data set is no longer being updated as of December 1, 2023. Access current COVID-19 data on the CDPH respiratory virus dashboard (https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Respiratory-Viruses/RespiratoryDashboard.aspx) or in open data format (https://data.chhs.ca.gov/dataset/respiratory-virus-dashboard-metrics).

As of August 17, 2023, data is being updated each Friday.

For death data after December 31, 2022, California uses Provisional Deaths from the Center for Disease Control and Prevention’s National Center for Health Statistics (NCHS) National Vital Statistics System (NVSS). Prior to January 1, 2023, death data was sourced from the COVID-19 registry. The change in data source occurred in July 2023 and was applied retroactively to all 2023 data to provide a consistent source of death data for the year of 2023.

As of May 11, 2023, data on cases, deaths, and testing is being updated each Thursday. Metrics by report date have been removed, but previous versions of files with report date metrics are archived below.

All metrics include people in state and federal prisons, US Immigration and Customs Enforcement facilities, US Marshal detention facilities, and Department of State Hospitals facilities. Members of California's tribal communities are also included.

The "Total Tests" and "Positive Tests" columns show totals based on the collection date. There is a lag between when a specimen is collected and when it is reported in this dataset. As a result, the most recent dates on the table will temporarily show NONE in the "Total Tests" and "Positive Tests" columns. This should not be interpreted as no tests being conducted on these dates. Instead, these values will be updated with the number of tests conducted as data is received.

NOTE: This dataset has been retired and marked as historical-only.

Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age.

Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine.

Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS).

Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death.

Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test.

CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset.

Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000.

Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people.

Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population.

Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to COVID-19, see https://data.cityofchic

Coronavirus (COVID-19) Data in the United States

[ U.S. State-Level Data (Raw CSV) | U.S. County-Level Data (Raw CSV) ]

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real-time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists, and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

United States Data

Data on cumulative coronavirus cases and deaths can be found in two files for states and counties.

Each row of data reports cumulative counts based on our best reporting up to the moment we publish an update. We do our best to revise earlier entries in the data when we receive new information.

Both files contain FIPS codes, a standard geographic identifier, to make it easier for an analyst to combine this data with other data sets like a map file or population data.

Download all the data or clone this repository by clicking the green "Clone or download" button above.

State-Level Data

State-level data can be found in the states.csv file. (Raw CSV file here.)

date,state,fips,cases,deaths
2020-01-21,Washington,53,1,0
...

County-Level Data

County-level data can be found in the counties.csv file. (Raw CSV file here.)

date,county,state,fips,cases,deaths
2020-01-21,Snohomish,Washington,53061,1,0
...

In some cases, the geographies where cases are reported do not map to standard county boundaries. See the list of geographic exceptions for more detail on these.

Methodology and Definitions

The data is the product of dozens of journalists working across several time zones to monitor news conferences, analyze data releases and seek clarification from public officials on how they categorize cases.

It is also a response to a fragmented American public health system in which overwhelmed public servants at the state, county and territorial levels have sometimes struggled to report information accurately, consistently and speedily. On several occasions, officials have corrected information hours or days after first reporting it. At times, cases have disappeared from a local government database, or officials have moved a patient first identified in one state or county to another, often with no explanation. In those instances, which have become more common as the number of cases has grown, our team has made every effort to update the data to reflect the most current, accurate information while ensuring that every known case is counted.

When the information is available, we count patients where they are being treated, not necessarily where they live.

In most instances, the process of recording cases has been straightforward. But because of the patchwork of reporting methods for this data across more than 50 state and territorial governments and hundreds of local health departments, our journalists sometimes had to make difficult interpretations about how to count and record cases.

For those reasons, our data will in some cases not exactly match the information reported by states and counties. Those differences include these cases: When the federal government arranged flights to the United States for Americans exposed to the coronavirus in China and Japan, our team recorded those cases in the states where the patients subsequently were treated, even though local health departments generally did not. When a resident of Florida died in Los Angeles, we recorded her death as having occurred in California rather than Florida, though officials in Florida counted her case in their records. And when officials in some states reported new cases without immediately identifying where the patients were being treated, we attempted to add information about their locations later, once it became available.

• Confirmed Cases

Confirmed cases are patients who test positive for the coronavirus. We consider a case confirmed when it is reported by a federal, state, territorial or local government agency.

• Dates

For each date, we show the cumulative number of confirmed cases and deaths as reported that day in that county or state. All cases and deaths are counted on the date they are first announced.

• Counties

In some instances, we report data from multiple counties or other non-county geographies as a single county. For instance, we report a single value for New York City, comprising the cases for New York, Kings, Queens, Bronx and Richmond Counties. In these instances, the FIPS code field will be empty. (We may assign FIPS codes to these geographies in the future.) See the list of geographic exceptions.

Cities like St. Louis and Baltimore that are administered separately from an adjacent county of the same name are counted separately.

• “Unknown” Counties

Many state health departments choose to report cases separately when the patient’s county of residence is unknown or pending determination. In these instances, we record the county name as “Unknown.” As more information about these cases becomes available, the cumulative number of cases in “Unknown” counties may fluctuate.

Sometimes, cases are first reported in one county and then moved to another county. As a result, the cumulative number of cases may change for a given county.

Geographic Exceptions

• New York City

All cases for the five boroughs of New York City (New York, Kings, Queens, Bronx and Richmond counties) are assigned to a single area called New York City.

• Kansas City, Mo.

Four counties (Cass, Clay, Jackson, and Platte) overlap the municipality of Kansas City, Mo. The cases and deaths that we show for these four counties are only for the portions exclusive of Kansas City. Cases and deaths for Kansas City are reported as their line.

• Alameda, Calif.

Counts for Alameda County include cases and deaths from Berkeley and the Grand Princess cruise ship.

• Chicago

All cases and deaths for Chicago are reported as part of Cook County.

License and Attribution

In general, we are making this data publicly available for broad, noncommercial public use including by medical and public health researchers, policymakers, analysts and local news media.

If you use this data, you must attribute it to “The New York Times” in any publication. If you would like a more expanded description of the data, you could say “Data from The New York Times, based on reports from state and local health agencies.”

If you use it in an online presentation, we would appreciate it if you would link to our U.S. tracking page at https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html.

If you use this data, please let us know at covid-data@nytimes.com and indicate if you would be willing to talk to a reporter about your research.

See our LICENSE for the full terms of use for this data.

This license is co-extensive with the Creative Commons Attribution-NonCommercial 4.0 International license, and licensees should refer to that license (CC BY-NC) if they have questions about the scope of the license.

Contact Us

If you have questions about the data or licensing conditions, please contact us at:

covid-data@nytimes.com

Contributors

Mitch Smith, Karen Yourish, Sarah Almukhtar, Keith Collins, Danielle Ivory, and Amy Harmon have been leading our U.S. data collection efforts.

Data has also been compiled by Jordan Allen, Jeff Arnold, Aliza Aufrichtig, Mike Baker, Robin Berjon, Matthew Bloch, Nicholas Bogel-Burroughs, Maddie Burakoff, Christopher Calabrese, Andrew Chavez, Robert Chiarito, Carmen Cincotti, Alastair Coote, Matt Craig, John Eligon, Tiff Fehr, Andrew Fischer, Matt Furber, Rich Harris, Lauryn Higgins, Jake Holland, Will Houp, Jon Huang, Danya Issawi, Jacob LaGesse, Hugh Mandeville, Patricia Mazzei, Allison McCann, Jesse McKinley, Miles McKinley, Sarah Mervosh, Andrea Michelson, Blacki Migliozzi, Steven Moity, Richard A. Oppel Jr., Jugal K. Patel, Nina Pavlich, Azi Paybarah, Sean Plambeck, Carrie Price, Scott Reinhard, Thomas Rivas, Michael Robles, Alison Saldanha, Alex Schwartz, Libby Seline, Shelly Seroussi, Rachel Shorey, Anjali Singhvi, Charlie Smart, Ben Smithgall, Steven Speicher, Michael Strickland, Albert Sun, Thu Trinh, Tracey Tully, Maura Turcotte, Miles Watkins, Jeremy White, Josh Williams, and Jin Wu.

Context

There's a story behind every dataset and here's your opportunity to share yours.# Coronavirus (Covid-19) Data in the United States

[ U.S. State-Level Data ([Raw

Note: This dataset is no longer being updated due to the end of the COVID-19 Public Health Emergency.

The California Department of Public Health (CDPH) is identifying vaccination status of COVID-19 cases, hospitalizations, and deaths by analyzing the state immunization registry and registry of confirmed COVID-19 cases. Post-vaccination cases are individuals who have a positive SARS-Cov-2 molecular test (e.g. PCR) at least 14 days after they have completed their primary vaccination series.

Tracking cases of COVID-19 that occur after vaccination is important for monitoring the impact of immunization campaigns. While COVID-19 vaccines are safe and effective, some cases are still expected in persons who have been vaccinated, as no vaccine is 100% effective. For more information, please see https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Post-Vaccine-COVID19-Cases.aspx

Post-vaccination infection data is updated monthly and includes data on cases, hospitalizations, and deaths among the unvaccinated and the vaccinated. Partially vaccinated individuals are excluded. To account for reporting and processing delays, there is at least a one-month lag in provided data (for example data published on 9/9/22 will include data through 7/31/22).

Notes:

• On September 9, 2022, the post-vaccination data has been changed to compare unvaccinated with those with at least a primary series completed for persons age 5+. These data will be updated monthly (first Thursday of the month) and include at least a one month lag.

• On February 2, 2022, the post-vaccination data has been changed to distinguish between vaccination with a primary series only versus vaccinated and boosted. The previous dataset has been uploaded as an archived table. Additionally, the lag on this data has been extended to 14 days.

• On November 29, 2021, the denominator for calculating vaccine coverage has been changed from age 16+ to age 12+ to reflect new vaccine eligibility criteria. The previous dataset based on age 16+ denominators has been uploaded as an archived table.

Reporting of Aggregate Case and Death Count data was discontinued on May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. Although these data will continue to be publicly available, this dataset will no longer be updated.

The surveillance case definition for COVID-19, a nationally notifiable disease, was first described in a position statement from the Council for State and Territorial Epidemiologists, which was later revised. However, there is some variation in how jurisdictions implemented these case definitions. More information on how CDC collects COVID-19 case surveillance data can be found at FAQ: COVID-19 Data and Surveillance.

Aggregate Data Collection Process Since the beginning of the COVID-19 pandemic, data were reported from state and local health departments through a robust process with the following steps:

• Aggregate county-level counts were obtained indirectly, via automated overnight web collection, or directly, via a data submission process.
• If more than one official county data source existed, CDC used a comprehensive data selection process comparing each official county data source to retrieve the highest case and death counts, unless otherwise specified by the state.
• A CDC data team reviewed counts for congruency prior to integration and set up alerts to monitor for discrepancies in the data.
• CDC routinely compiled these data and post the finalized information on COVID Data Tracker.
• County level data were aggregated to obtain state- and territory- specific totals.
• Counting of cases and deaths is based on date of report and not on the date of symptom onset. CDC calculates rates in these data by using population estimates provided by the US Census Bureau Population Estimates Program (2019 Vintage).
• COVID-19 aggregate case and death data are organized in a time series that includes cumulative number of cases and deaths as reported by a jurisdiction on a given date. New case and death counts are calculated as the week-to-week change in cumulative counts of cases and deaths reported (i.e., newly reported cases and deaths = cumulative number of cases/deaths reported this week minus the cumulative total reported the prior week.

This process was collaborative, with CDC and jurisdictions working together to ensure the accuracy of COVID-19 case and death numbers. County counts provided the most up-to-date numbers on cases and deaths by report date. Throughout data collection, CDC retrospectively updated counts to correct known data quality issues.

Description This archived public use dataset focuses on the cumulative and weekly case and death rates per 100,000 persons within various sociodemographic factors across all states and their counties. All resulting data are expressed as rates calculated as the number of cases or deaths per 100,000 persons in counties meeting various classification criteria using the US Census Bureau Population Estimates Program (2019 Vintage).

Each county within jurisdictions is classified into multiple categories for each factor. All rates in this dataset are based on classification of counties by the characteristics of their population, not individual-level factors. This applies to each of the available factors observed in this dataset. Specific factors and their corresponding categories are detailed below.

Population-level factors Each unique population factor is detailed below. Please note that the “Classification” column describes each of the 12 factors in the dataset, including a data dict

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138

As of July 2nd, 2024 the COVID-19 Deaths by Population Characteristics Over Time dataset has been retired. This dataset is archived and will no longer update. We will be publishing a cumulative deaths by population characteristics dataset that will update moving forward.

A. SUMMARY This dataset shows San Francisco COVID-19 deaths by population characteristics and by date. This data may not be immediately available for recently reported deaths. Data updates as more information becomes available. Because of this, death totals for previous days may increase or decrease. More recent data is less reliable.

Population characteristics are subgroups, or demographic cross-sections, like age, race, or gender. The City tracks how deaths have been distributed among different subgroups. This information can reveal trends and disparities among groups.

B. HOW THE DATASET IS CREATED As of January 1, 2023, COVID-19 deaths are defined as persons who had COVID-19 listed as a cause of death or a significant condition contributing to their death on their death certificate. This definition is in alignment with the California Department of Public Health and the national https://preparedness.cste.org/wp-content/uploads/2022/12/CSTE-Revised-Classification-of-COVID-19-associated-Deaths.Final_.11.22.22.pdf">Council of State and Territorial Epidemiologists. Death certificates are maintained by the California Department of Public Health.

Data on the population characteristics of COVID-19 deaths are from: *Case reports *Medical records *Electronic lab reports *Death certificates

Data are continually updated to maximize completeness of information and reporting on San Francisco COVID-19 deaths.

To protect resident privacy, we summarize COVID-19 data by only one characteristic at a time. Data are not shown until cumulative citywide deaths reach five or more.

Data notes on each population characteristic type is listed below.

Race/ethnicity * We include all race/ethnicity categories that are collected for COVID-19 cases.

Gender * The City collects information on gender identity using these guidelines.

C. UPDATE PROCESS Updates automatically at 06:30 and 07:30 AM Pacific Time on Wednesday each week.

Dataset will not update on the business day following any federal holiday.

D. HOW TO USE THIS DATASET Population estimates are only available for age groups and race/ethnicity categories. San Francisco population estimates for race/ethnicity and age groups can be found in a view based on the San Francisco Population and Demographic Census dataset. These population estimates are from the 2016-2020 5-year American Community Survey (ACS).

This dataset includes many different types of characteristics. Filter the “Characteristic Type” column to explore a topic area. Then, the “Characteristic Group” column shows each group or category within that topic area and the number of deaths on each date.

New deaths are the count of deaths within that characteristic group on that specific date. Cumulative deaths are the running total of all San Francisco COVID-19 deaths in that characteristic group up to the date listed.

This data may not be immediately available for more recent deaths. Data updates as more information becomes available.

To explore data on the total number of deaths, use the COVID-19 Deaths Over Time dataset.

E. CHANGE LOG

• 9/11/2023 - on this date, we began using an updated definition of a COVID-19 death to align with the California Department o

This dataset contains information on antibody testing for COVID-19: the number of people who received a test, the number of people with positive results, the percentage of people tested who tested positive, and the rate of testing per 100,000 people, stratified by sex. These data can also be accessed here: https://github.com/nychealth/coronavirus-data/blob/master/totals/antibody-by-sex.csv Exposure to COVID-19 can be detected by measuring antibodies to the disease in a person’s blood, which can indicate that a person may have had an immune response to the virus. Antibodies are proteins produced by the body’s immune system that can be found in the blood. People can test positive for antibodies after they have been exposed, sometimes when they no longer test positive for the virus itself. It is important to note that the science around COVID-19 antibody tests is evolving rapidly and there is still much uncertainty about what individual antibody test results mean for a single person and what population-level antibody test results mean for understanding the epidemiology of COVID-19 at a population level. These data only provide information on people tested. People receiving an antibody test do not reflect all people in New York City; therefore, these data may not reflect antibody prevalence among all New Yorkers. Increasing instances of screening programs further impact the generalizability of these data, as screening programs influence who and how many people are tested over time. Examples of screening programs in NYC include: employers screening their workers (e.g., hospitals), and long-term care facilities screening their residents. In addition, there may be potential biases toward people receiving an antibody test who have a positive result because people who were previously ill are preferentially seeking testing, in addition to the testing of persons with higher exposure (e.g., health care workers, first responders.) Rates were calculated using interpolated intercensal population estimates updated in 2019. These rates differ from previously reported rates based on the 2000 Census or previous versions of population estimates. The Health Department produced these population estimates based on estimates from the U.S. Census Bureau and NYC Department of City Planning. Antibody tests are categorized based on the date of specimen collection and are aggregated by full weeks starting each Sunday and ending on Saturday. For example, a person whose blood was collected for antibody testing on Wednesday, May 6 would be categorized as tested during the week ending May 9. A person tested twice in one week would only be counted once in that week. This dataset includes testing data beginning April 5, 2020. Data are updated daily, and the dataset preserves historical records and source data changes, so each extract date reflects the current copy of the data as of that date. For example, an extract date of 11/04/2020 and extract date of 11/03/2020 will both contain all records as they were as of that extract date. Without filtering or grouping by extract date, an analysis will almost certainly be miscalculating or counting the same values multiple times. To analyze the most current data, only use the latest extract date. Antibody tests that are missing dates are not included in the dataset; as dates are identified, these events are added. Lags between occurrence and report of cases and tests can be assessed by comparing counts and rates across multiple data extract dates. For further details, visit: • https://www1.nyc.gov/site/doh/covid/covid-19-data.page • https://github.com/nychealth/coronavirus-data

DPH note about change from 7-day to 14-day metrics: As of 10/15/2020, this dataset is no longer being updated. Starting on 10/15/2020, these metrics will be calculated using a 14-day average rather than a 7-day average. The new dataset using 14-day averages can be accessed here: https://data.ct.gov/Health-and-Human-Services/COVID-19-case-rate-per-100-000-population-and-perc/hree-nys2

As you know, we are learning more about COVID-19 all the time, including the best ways to measure COVID-19 activity in our communities. CT DPH has decided to shift to 14-day rates because these are more stable, particularly at the town level, as compared to 7-day rates. In addition, since the school indicators were initially published by DPH last summer, CDC has recommended 14-day rates and other states (e.g., Massachusetts) have started to implement 14-day metrics for monitoring COVID transmission as well.

With respect to geography, we also have learned that many people are looking at the town-level data to inform decision making, despite emphasis on the county-level metrics in the published addenda. This is understandable as there has been variation within counties in COVID-19 activity (for example, rates that are higher in one town than in most other towns in the county).

This dataset includes a weekly count and weekly rate per 100,000 population for COVID-19 cases, a weekly count of COVID-19 PCR diagnostic tests, and a weekly percent positivity rate for tests among people living in community settings. Dates are based on date of specimen collection (cases and positivity).

A person is considered a new case only upon their first COVID-19 testing result because a case is defined as an instance or bout of illness. If they are tested again subsequently and are still positive, it still counts toward the test positivity metric but they are not considered another case.

These case and test counts do not include cases or tests among people residing in congregate settings, such as nursing homes, assisted living facilities, or correctional facilities.

These data are updated weekly; the previous week period for each dataset is the previous Sunday-Saturday, known as an MMWR week (https://wwwn.cdc.gov/nndss/document/MMWR_week_overview.pdf). The date listed is the date the dataset was last updated and corresponds to a reporting period of the previous MMWR week. For instance, the data for 8/20/2020 corresponds to a reporting period of 8/9/2020-8/15/2020.

Notes: 9/25/2020: Data for Mansfield and Middletown for the week of Sept 13-19 were unavailable at the time of reporting due to delays in lab reporting.

Note: The cumulative case count for some counties (with small population) is higher than expected due to the inclusion of non-permanent residents in COVID-19 case counts.

Reporting of Aggregate Case and Death Count data was discontinued on May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. Although these data will continue to be publicly available, this dataset will no longer be updated.

Aggregate Data Collection Process Since the beginning of the COVID-19 pandemic, data were reported through a robust process with the following steps:

• Aggregate county-level counts were obtained indirectly, via automated overnight web collection, or directly, via a data submission process.
• If more than one official county data source existed, CDC used a comprehensive data selection process comparing each official county data source to retrieve the highest case and death counts, unless otherwise specified by the state.
• A CDC data team reviewed counts for congruency prior to integration. CDC routinely compiled these data and post the finalized information on COVID Data Tracker.
• Cases and deaths are based on date of report and not on the date of symptom onset. CDC calculates rates in this data by using population estimates provided by the US Census Bureau Population Estimates Program (2019 Vintage).
• COVID-19 aggregate case and death data were organized in a time series that includes cumulative number of cases and deaths as reported by a jurisdiction on a given date. New case and death counts were calculated as the week-to-week change in reported cumulative cases and deaths (i.e., newly reported cases and deaths = cumulative number of cases/deaths reported this week minus the cumulative total reported the week before.

This process was collaborative, with CDC and jurisdictions working together to ensure the accuracy of COVID-19 case and death numbers. County counts provided the most up-to-date numbers on cases and deaths by report date. Throughout data collection, CDC retrospectively updated counts to correct known data quality issues. CDC also worked with jurisdictions after the end of the public health emergency declaration to finalize county data.

• Source: The weekly archived dataset is based on county-level aggregate count data
• Confirmed/Probable Cases/Death breakdown: Cumulative cases and deaths for each county are included. Total reported cases include probable and confirmed cases.
• Time Series Frequency: The weekly archived dataset contains weekly time series data (i.e., one record per week per county)

Important note: The counts reflected during a given time period in this dataset may not match the counts reflected for the same time period in the daily archived dataset noted above. Discrepancies may exist due to differences between county and state COVID-19 case surveillance and reconciliation efforts.

The surveillance case definition for COVID-19, a nationally notifiable disease, was first described in a position statement from the Council for State and Territorial Epidemiologists, which was later revised. However, there is some variation in how jurisdictions implement these case classifications. More information on how CDC collects COVID-19 case surveillance data can be found at FAQ: COVID-19 Data and Surveillance.

Confirmed and Probable Counts In this dataset, counts by jurisdiction are not displayed by confirmed or probable status. Instead, counts of confirmed and probable cases and deaths are included in the Total Cases and Total Deaths columns, when available. Not all jurisdictions reported probable cases and deaths to CDC. Confirmed and probable case definition criteria are described here: "https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-covid-19/">Coronavirus Disease 2019 (COVID-19) 2023 Case Definition | CDC Council of State and Territorial Epidemiologists (ymaws.com).

Deaths COVID-19 deaths were reported to CDC from several sources since the beginning of the pandemic including aggregate death data and NCHS Provisional Death Counts. Historic information presented on the COVID Data Tracker pages were based on the same source (Aggregate Data) as the present dataset until the expiration of the public health emergency declaration on May 11, 2023; however, the NCHS Death Counts are based on death certificate data that use information reported by physicians, medical examiners, or coroners in the cause-of-death section of each certificate. Counts from previous weeks were continually revised as more records were received and processed.

Number of Jurisdictions Reporting There were 60 public health jurisdictions that reported cases and deaths of COVID-19. This included the 50 states, the District of Columbia, New York City, the U.S. territories of American Samoa, Guam, the Commonwealth of the Northern Mariana Islands, Puerto Rico, and the U.S Virgin Islands as well as three independent countries in compacts of free association with the United States, Federated States of Micronesia, Republic of the Marshall Islands, and Republic of Palau. In total there were 3,222 counties for which counts were tracked within the 60 public health jurisdictions.

Additional COVID-19 public use datasets, include line-level (patient-level) data, are available at: https://data.cdc.gov/browse?tags=covid-19.

Note: In early 2020, Alaska enacted changes to their counties/boroughs due to low populations in certain areas:

Case and death counts for Yakutat City and Borough, Alaska, are shown as 0 by default. Case and death counts for Hoonah-Angoon Census Area, Alaska, represent total cases and deaths in residents of Hoonah-Angoon Census Area, Alaska, and Yakutat City and Borough, Alaska. Case and death counts for Bristol Bay Borough, Alaska, are shown as 0 by default. Case and death counts for Lake and Peninsula Borough, Alaska, represent total cases and deaths in residents of Lake and Peninsula Borough, Alaska, and Bristol Bay Borough, Alaska.

Historical cases and deaths are not tracked separately in the county level datasets, and differences in weekly new cases and deaths could exist when county-level data are aggregated to the state-level (i.e., when compared to this dataset: https://data.cdc.gov/Case-Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfq-cb36).

The World Health Organization reported 6932591 Coronavirus Deaths since the epidemic began. In addition, countries reported 766440796 Coronavirus Cases. This dataset provides - World Coronavirus Deaths- actual values, historical data, forecast, chart, statistics, economic calendar and news.

Reporting of new Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. This dataset will receive a final update on June 1, 2023, to reconcile historical data through May 10, 2023, and will remain publicly available.

Aggregate Data Collection Process Since the start of the COVID-19 pandemic, data have been gathered through a robust process with the following steps:

• A CDC data team reviews and validates the information obtained from jurisdictions’ state and local websites via an overnight data review process.
• If more than one official county data source exists, CDC uses a comprehensive data selection process comparing each official county data source, and takes the highest case and death counts respectively, unless otherwise specified by the state.
• CDC compiles these data and posts the finalized information on COVID Data Tracker.
• County level data is aggregated to obtain state and territory specific totals.

This process is collaborative, with CDC and jurisdictions working together to ensure the accuracy of COVID-19 case and death numbers. County counts provide the most up-to-date numbers on cases and deaths by report date. CDC may retrospectively update counts to correct data quality issues.

Methodology Changes Several differences exist between the current, weekly-updated dataset and the archived version:

• Source: The current Weekly-Updated Version is based on county-level aggregate count data, while the Archived Version is based on State-level aggregate count data.
• Confirmed/Probable Cases/Death breakdown:  While the probable cases and deaths are included in the total case and total death counts in both versions (if applicable), they were reported separately from the confirmed cases and deaths by jurisdiction in the Archived Version.  In the current Weekly-Updated Version, the counts by jurisdiction are not reported by confirmed or probable status (See Confirmed and Probable Counts section for more detail).
• Time Series Frequency: The current Weekly-Updated Version contains weekly time series data (i.e., one record per week per jurisdiction), while the Archived Version contains daily time series data (i.e., one record per day per jurisdiction).
• Update Frequency: The current Weekly-Updated Version is updated weekly, while the Archived Version was updated twice daily up to October 20, 2022.

Important note: The counts reflected during a given time period in this dataset may not match the counts reflected for the same time period in the archived dataset noted above. Discrepancies may exist due to differences between county and state COVID-19 case surveillance and reconciliation efforts.

Confirmed and Probable Counts In this dataset, counts by jurisdiction are not displayed by confirmed or probable status. Instead, confirmed and probable cases and deaths are included in the Total Cases and Total Deaths columns, when available. Not all jurisdictions report probable cases and deaths to CDC.* Confirmed and probable case definition criteria are described here:

Council of State and Territorial Epidemiologists (ymaws.com).

Deaths CDC reports death data on other sections of the website: CDC COVID Data Tracker: Home, CDC COVID Data Tracker: Cases, Deaths, and Testing, and NCHS Provisional Death Counts. Information presented on the COVID Data Tracker pages is based on the same source (to

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be updated as more jurisdictions participate.

Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with at least a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6-12 months, half of the single-year population counts for ages <12 months were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred.

Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage.

Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated without an updated (bivalent) booster dose) or vaccinated with an updated (bivalent) booster dose.

Archive: An archive of historic data, including April 3, 2021-September 24, 2022 and posted on October 21, 2022 is available on data.cdc.gov. The analysis by vaccination status (unvaccinated and at least a primary series) for 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/3rge-nu2a. The analysis for one booster dose (unvaccinated, primary series only, and at least one booster dose) in 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm. The analysis for two booster doses (unvaccinated, primary series only, one booster dose, and at least two booster doses) in 28 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/ukww-au2k.

References

Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290.

Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138

Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152

Context

This is a dataset of the most highly populated city (if applicable) in a form easy to join with the COVID19 Global Forecasting (Week 1) dataset. You can see how to use it in this kernel

Content

There are four columns. The first two correspond to the columns from the original COVID19 Global Forecasting (Week 1) dataset. The other two is the highest population density, at city level, for the given country/state. Note that some countries are very small and in those cases the population density reflects the entire country. Since the original dataset has a few cruise ships as well, I've added them there.

Acknowledgements

Thanks a lot to Kaggle for this competition that gave me the opportunity to look closely at some data and understand this problem better.

Inspiration

Summary: I believe that the square root of the population density should relate to the logistic growth factor of the SIR model. I think the SEIR model isn't applicable due to any intervention being too late for a fast-spreading virus like this, especially in places with dense populations.

After playing with the data provided in COVID19 Global Forecasting (Week 1) (and everything else online or media) a bit, one thing becomes clear. They have nothing to do with epidemiology. They reflect sociopolitical characteristics of a country/state and, more specifically, the reactivity and attitude towards testing.

The testing method used (PCR tests) means that what we measure could potentially be a proxy for the number of people infected during the last 3 weeks, i.e the growth (with lag). It's not how many people have been infected and recovered. Antibody or serology tests would measure that, and by using them, we could go back to normality faster... but those will arrive too late. Way earlier, China will have experimentally shown that it's safe to go back to normal as soon as your number of newly infected per day is close to zero.

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F197482%2F429e0fdd7f1ce86eba882857ac7a735e%2Fcovid-summary.png?generation=1585072438685236&alt=media" alt="">

My view, as a person living in NYC, about this virus, is that by the time governments react to media pressure, to lockdown or even test, it's too late. In dense areas, everyone susceptible has already amble opportunities to be infected. Especially for a virus with 5-14 days lag between infections and symptoms, a period during which hosts spread it all over on subway, the conditions are hopeless. Active populations have already been exposed, mostly asymptomatic and recovered. Sensitive/older populations are more self-isolated/careful in affluent societies (maybe this isn't the case in North Italy). As the virus finishes exploring the active population, it starts penetrating the more isolated ones. At this point in time, the first fatalities happen. Then testing starts. Then the media and the lockdown. Lockdown seems overly effective because it coincides with the tail of the disease spread. It helps slow down the virus exploring the long-tail of sensitive population, and we should all contribute by doing it, but it doesn't cause the end of the disease. If it did, then as soon as people were back in the streets (see China), there would be repeated outbreaks.

Smart politicians will test a lot because it will make their condition look worse. It helps them demand more resources. At the same time, they will have a low rate of fatalities due to large denominator. They can take credit for managing well a disproportionally major crisis - in contrast to people who didn't test.

We were lucky this time. We, Westerners, have woken up to the potential of a pandemic. I'm sure we will give further resources for prevention. Additionally, we will be more open-minded, helping politicians to have more direct responses. We will also require them to be more responsible in their messages and reactions.

A. SUMMARY This archived dataset includes data for population characteristics that are no longer being reported publicly. The date on which each population characteristic type was archived can be found in the field “data_loaded_at”. B. HOW THE DATASET IS CREATED Data on the population characteristics of COVID-19 cases are from:  * Case interviews  * Laboratories  * Medical providers    These multiple streams of data are merged, deduplicated, and undergo data verification processes.   Race/ethnicity * We include all race/ethnicity categories that are collected for COVID-19 cases. * The population estimates for the "Other" or “Multi-racial” groups should be considered with caution. The Census definition is likely not exactly aligned with how the City collects this data. For that reason, we do not recommend calculating population rates for these groups. Gender * The City collects information on gender identity using these guidelines. Skilled Nursing Facility (SNF) occupancy * A Skilled Nursing Facility (SNF) is a type of long-term care facility that provides care to individuals, generally in their 60s and older, who need functional assistance in their daily lives.  * This dataset includes data for COVID-19 cases reported in Skilled Nursing Facilities (SNFs) through 12/31/2022, archived on 1/5/2023. These data were identified where “Characteristic_Type” = ‘Skilled Nursing Facility Occupancy’. Sexual orientation * The City began asking adults 18 years old or older for their sexual orientation identification during case interviews as of April 28, 2020. Sexual orientation data prior to this date is unavailable. * The City doesn’t collect or report information about sexual orientation for persons under 12 years of age. * Case investigation interviews transitioned to the California Department of Public Health, Virtual Assistant information gathering beginning December 2021. The Virtual Assistant is only sent to adults who are 18+ years old. Learn more about our data collection guidelines pertaining to sexual orientation. Comorbidities * Underlying conditions are reported when a person has one or more underlying health conditions at the time of diagnosis or death. Homelessness Persons are identified as homeless based on several data sources: * self-reported living situation * the location at the time of testing * Department of Public Health homelessness and health databases * Residents in Single-Room Occupancy hotels are not included in these figures. These methods serve as an estimate of persons experiencing homelessness. They may not meet other homelessness definitions. Single Room Occupancy (SRO) tenancy * SRO buildings are defined by the San Francisco Housing Code as having six or more "residential guest rooms" which may be attached to shared bathrooms, kitchens, and living spaces. * The details of a person's living arrangements are verified during case interviews. Transmission Type * Information on transmission of COVID-19 is based on case interviews with individuals who have a confirmed positive test. Individuals are asked if they have been in close contact with a known COVID-19 case. If they answer yes, transmission category is recorded as contact with a known case. If they report no contact with a known case, transmission category is recorded as community transmission. If the case is not interviewed or was not asked the question, they are counted as unknown. C. UPDATE PROCESS This dataset has been archived and will no longer update as of 9/11/2023. D. HOW TO USE THIS DATASET Population estimates are only available for age groups and race/ethnicity categories. San Francisco po

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 19 elements for all COVID-19 cases shared with CDC and includes demographics, geography (county and state of residence), any exposure history, disease severity indicators and outcomes, and presence of any underlying medical conditions and risk behaviors.

Currently, CDC provides the public with three versions of COVID-19 case surveillance line-listed data: this 19 data element dataset with geography, a 12 data element public use dataset, and a 33 data element restricted access dataset.

The following apply to the public use datasets and the restricted access dataset:

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data are suppressed to protect individual privacy.
• Datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensure that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (<a href="https://cdn.ymaws.com/www.cste.org/resource/resmgr/ps/positionstatement2020/Interim-20-ID-01_COVID

Rationale: The World Health Organization (WHO) has declared the current coronavirus disease (COVID-19) outbreak, caused by the SARS-CoV-2 virus, to be a pandemic and, therefore, a Public Health Emergency of International Concern. The COVID-19 outbreak has a huge impact on health care, but also on economic and social costs. Track-and-trace programs are important measures to control the virus, but they have their limitations such as delays in the test results (e.g., it takes time to develop symptoms after infection, to access a test, receive the test result, and for close contacts to be traced). Early traceability of the virus may help in the track-and-trace programs to control the virus. It is currently thought that most – but not all – infected individuals develop symptoms, but that the infectious period starts on average two days before the first overt symptoms appear. It is estimated that pre- and asymptomatic individuals are responsible for up to half of all transmissions. By detecting infected individuals before they have overt symptoms, the proportion of transmissions by pre-symptomatic individuals could potentially be significantly reduced. Primary Objective: Using laboratory-confirmed SARS-CoV-2 infections (detected via serology, PCR and/or antigen tests) as the gold standard, we will determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for each of the following two algorithms to detect first time SARS-CoV-2 infection including early or asymptomatic infection: the algorithm using Ava bracelet data when coupled with self-reported Daily Symptom Diary data, and the algorithm using self-reported Daily Symptom Diary data alone. In addition, we will determine which of the two algorithms has superior performance characteristics for detecting SARS-CoV-2 infection including early or asymptomatic infection as confirmed by SARS-CoV-2 virus testing. Study design: Randomized, single-blinded, two-period, two-sequence crossover trial. The study will start with an initial Learning Phase (maximum 3 months), followed by a 3-month Period 1 and a 3-month Period 2. Each subject will undergo the experimental condition (=algorithm uses data from app and bracelet) in one of these periods and the control condition (=algorithm uses data from the app only) in the other period, but the order will be randomly assigned, resulting in Sequence 1 (experimental condition first) and Sequence 2 (control condition first). Study population: A target of 20,000 subjects will be enrolled in this study. Subjects will be recruited from previously studied cohorts as well as via public campaigns. They will be invited to visit the COVID-RED web portal. When they have successfully completed the survey questions in the COVID-RED web portal, are considered eligible and have indicated interest in joining the study, then they will receive the subject information sheet and consent form. Subjects can be enrolled when they comply with the following inclusion and exclusion criteria: Key Inclusion criteria: • Resident of the Netherlands • At least 18 years old • Must have a smartphone that runs at least Android 8.0 or iOS 13.0 operating systems and is active for the duration of the study (in the case of a change of mobile number, study team should be notified) • Be able to read, understand and write Dutch Key Exclusion criteria • Previous positive SARS-CoV-2 test result (confirmed either through PCR/antigen or antibody tests) (self-reported) • Current suspected (e.g., waiting for test result) coronavirus infection or symptoms of a coronavirus infection (self-reported) • Electronic implanted device (such as a pacemaker) • Suffering from cholinergic urticaria Intervention: All subjects will be instructed to complete the Daily Symptom Diary in the Ava COVID-RED app, wear their Ava bracelet each night and synchronise it with the app each day, during the entire period of study participation. The experimental condition (=algorithm uses app and bracelet data) will be compared to the control condition (=algorithm uses app data only). Main study parameters/endpoints: The primary endpoint for this study for each subject is the daily indication of potential SARS-CoV-2 infection as provided by the algorithm of the Ava COVID-RED app with or without using data from the Ava bracelet. This daily endpoint will be compared with actual SARS-CoV-2 test results (PCR/antigen and/or serology) collected before, during and at the end of study participation. For the primary comparison, this daily endpoint will be summarized over each trial period per subject to determine (1) whether a subject was ever judged to have had a high risk for a potential SARS-Cov-2 infection, and (2) whether a subject was ever confirmed to have had a SARS-CoV-2 infection by PCR/antigen and/or serology testing. For this comparison, parameters such as sensitivity, specificity, positive predictive value, and negative predictive value will be calculated. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects wearing the Ava bracelet may experience skin irritation or sensitization due to rubbing and friction. Subjects are instructed to only wear the device at night to allow the skin to dry and breath during the day. They will be instructed to discontinue wearing the Ava bracelet and contact the study team in case they experience any signs of allergic reaction, feel soreness, tingling, numbness, burning or stiffness in their hands or wrists while or after wearing the Ava bracelet. Subjects may feel uncomfortable answering health questions in the Ava COVID-RED app, but they have the choice of not responding to the questions in the app. Subjects will be asked to donate fingerprick blood for SARS-CoV-2 antibody testing at up to 4 different timepoints, which may cause minor discomfort. This study will use the existing testing infrastructure in the Netherlands provided by the Municipal Health services (GGD) for SARS-CoV-2 infection, and, only when this is not possible, PCR testing in the central study laboratory will be arranged. Recruitment and follow-up will be completely remote and take place via post, email, phone and electronic web portals. In this way, risk of SARS-CoV-2 infection is minimized as much as possible for those wanting to participate in the trial and for the staff conducting the trial. Another risk for the subject is the potential breach of data security. The study team will implement security measures to prevent loss of data or unauthorised access to the data and we will follow the General Data Protection Regulation (GDPR). Data will be pseudo-anonymized within the platforms where data analysis will be performed. Data transfers will use a trial-specific identifier which is not linked to any external participant identifiers. Overall, the burden for the subjects is assessed as small and is justified given the importance of assessing a potential method in early detection of COVID-19. The expected benefit is large as the algorithms trained on the obtained data recordings from the Ava bracelet are expected to recognize COVID-19 earlier than the presentation of clinical symptoms. The latter would allow for earlier isolation and stratification as well as monitoring of SARS-CoV-2 infected persons preventing further spread and, if applicable, allowing for appropriate healthcare.